Literature DB >> 30685340

Role of Intracoronary Fibrinolytic Therapy in Contemporary PCI Practice.

Sanjeev Kumar Agarwal1, Shubham Agarwal2.   

Abstract

Plaque rupture or plaque erosion leads to intracoronary thrombus formation resulting in coronary artery occlusion and ST-segment elevation myocardial infarction. Early restoration of blood flow in occluded coronary artery is the mainstay of therapy and it can be achieved by either thrombolytic therapy or primary percutaneous coronary intervention (P-PCI) or a combination of these two in many different ways. It has been proved that primary PCI is better than thrombolytic therapy in establishing early and effective recanalization of infarct related artery, reducing major adverse cardiovascular events (MACE) and increasing survival. There have been tremendous advances in PCI techniques over the years with newer stents, thrombectomy devices, and adjunctive pharmacotherapy. However, intracoronary thrombus continues to be the bane of interventional cardiologists. Failure of recanalization, suboptimal results, distal embolization, no reflow and impaired myocardial perfusion are some of the unresolved difficulties, regularly seen during PCI of patients with large intracoronary thrombus burden indicating an unmet need. This review focuses on emerging evidence about the usefulness of intracoronary thrombolytic therapy as an adjunct to PCI in patients with large intracoronary thrombus burden.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Coronary thrombosis; Myocardial infarction; Percutaneous coronary intervention; Thrombolytic therapy; Tissue plasminogen activator

Mesh:

Substances:

Year:  2018        PMID: 30685340     DOI: 10.1016/j.carrev.2018.11.021

Source DB:  PubMed          Journal:  Cardiovasc Revasc Med        ISSN: 1878-0938


  7 in total

1.  STEMI with flush occlusion of a coronary artery: An interventional dilemma.

Authors:  Shubham Agarwal; Sanjeev Kumar Agarwal
Journal:  J Cardiol Cases       Date:  2020-11-03

2.  The role of intracoronary thrombolysis in selected patients presenting with ST-elevation myocardial infarction: a case series.

Authors:  Sumita Barua; Paul Geenty; Tejas Deshmukh; Cuneyt Ada; David Tanous; Mark Cooper; Peter Fahmy; Alan Robert Denniss
Journal:  Eur Heart J Case Rep       Date:  2020-09-04

3.  Intracoronary fibrinolysis: An effective yet underutilized therapeutic strategy in clinical practice.

Authors:  Kenan Yalta; Cihan Öztürk; Tülin Yalta; Uğur Özkan
Journal:  Anatol J Cardiol       Date:  2021-08       Impact factor: 1.475

4.  Comparison of QT dispersion in patients with ST elevation acute myocardial infarction (STEMI) before and after treatment by streptokinase versus primary percutaneous coronary intervention (PCI).

Authors:  Abbas Valizadeh; Sahar Soltanabadi; Saeed Koushafar; Maryam Rezaee; Reza Jahankhah
Journal:  BMC Cardiovasc Disord       Date:  2020-11-23       Impact factor: 2.298

5.  Intracoronary artery retrograde thrombolysis combined with percutaneous coronary interventions for ST-segment elevation myocardial infarction complicated with diabetes mellitus: A case report and literature review.

Authors:  Mingzhi Shen; Yichao Liao; Jian Wang; Xinger Zhou; Yuting Guo; Yingqiao Nong; Yi Guo; Haihui Lu; Rongjie Jin; Jihang Wang; Zhenhong Fu; Dongyun Li; Shihao Zhao; Jinwen Tian
Journal:  Front Cardiovasc Med       Date:  2022-07-22

Review 6.  Low-Dose Slow Infusion Tissue Plasminogen Activator (tPA) in Treatment of Thrombotic Coronary Artery Occlusions: Case Series and Literature Review.

Authors:  Murat Akçay; Metin Çoksevim; Ufuk Yıldırım; Ömer Gedikli; Okan Gülel; Serkan Yüksel; Murat Meriç; Korhan Soylu; Özcan Yılmaz; Mahmut Şahin
Journal:  Anatol J Cardiol       Date:  2022-04       Impact factor: 1.475

7.  Influences of different dose of tirofiban for acute ST elevation myocardial infarction patients underwent percutaneous coronary intervention.

Authors:  Haixia Wang; Meiqin Feng
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.